Sumitomo Dainippon Pharma Annual Report 2017

Compliance with the PhRMA CodeActivities in MarketingActivities in MarketingCSRCSROur subsidiary Sunovion is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA), whose mission is to conduct effective advocacy for public policies to facilitate the discovery of new medicines for patients by pharmaceutical and biotechnology companies.Since 2001, PhRMA has had in place the PhRMA Code on Interactions with Healthcare Professionals (the PhRMA Code), which is a voluntary standard that sets out interactions with U.S. healthcare institutions. Sunovion is a signatory company of the Code and has formulated policies and guidelines in order to comply with the PhRMA Code in its promotion activities in the U.S.PhRMA also recommends that member companies undergo an external verification of their policies and guidelines on compliance with the PhRMA Code at least once every three years. Sunovion completed its external verification in February 2016, and it was determined that the company had policies and business processes in place to foster compliance with the PhRMA Code. Sunovion submitted the results of its external verification to PhRMA in March 2016 and is one of 23 companies to have completed the external verification.Implementing Patient SupportSunovion partners with patient advocacy organizations across the U.S., while also developing and assisting premier advocacy programs in order to advance education and awareness across the psychiatry & neurology and respiratory therapeutic areas. Employees participate in various events that raise awareness and funds for these programs.For BROVANA®, we will continue its initiatives of FY2016 to further expand sales by stressing its effectiveness and convenience in COPD treatment to medical professionals. Moreover, we are awaiting New Drug Application (NDA) approval for SUN-101 and expect it to come on the market in FY2017. It is a long-acting muscarinic antagonist (LAMA) treatment for COPD administered via nebulizer and having a different mechanism of action from BROVANA® (a long-acting beta-agonist: LABA).Also scheduled for launch or start of promotion in FY2017 are three FDA-approved COPD medicines, which all use fixed dose inhalers and are licensed from Novartis. With the addition of these products, Sunovion has the broadest COPD portfolio in the U.S., providing treatment options for people at various stages of COPD, as well as the flexibility for health care providers and patients to choose handheld or nebulized delivery, based on individual needs. UTIBRONTM NEOHALER® was launched in April 2017. Sunovion expects to launch SEEBRITM NEOHALER® and begin promotion of ARCAPTA® NEOHALER® in FY2017.38Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#39